Clobazam (Onfi – Lundbeck), an oral benzodiazepine, has been approved by the FDA for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ≥2 years old. It has been available in Canada (Frisium) and other countries for years for treatment of anxiety and many types of epilepsy.

LENNOX-GASTAUT SYNDROME — LGS is a severe form of childhood epilepsy characterized by multiple types of seizures, developmental delays and impaired intellectual function. Most LGS patients require combinations of antiepileptic drugs to control their seizures. Drop attacks (atonic, tonic or myoclonic seizures resulting in sudden falls) occur in about half of patients with LGS. Most pediatric neurologists consider valproic acid (Depakene, and others) the first-line treatment, but only topiramate (Topamax, and others), lamotrigine (Lamictal, and others), ... more      

Would you like to read the rest of this article?  Gain access below.